Do you want to read an article? Please log in or register.
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study
J Crohns Colitis
Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I
doi: 10.1093/ecco-jcc/jjaf138
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036
Inflammatory Bowel Disease
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
J Crohns Colitis
Colombel JF, Wu J, Kobayashi T, Zhu B, Paulissen J, Dhanabal A, Jairath V, Siegel C, Siegmund B, Redondo I, Moses R, Magro F
doi: 10.1093/ecco-jcc/jjaf124
COMMENTED
Inflammatory Bowel Disease
Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Inflamm Intest Dis
Grob F, Häberling I, Novacek G, Kreienbühl A, Biedermann L, Rogler G, Schreiner P
doi: 10.1159/000546511
Inflammatory Bowel Disease
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
Adv Ther
Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, Kroep S, Halfpenny N, Arcà E, Hoque S
doi: 10.1007/s12325-024-03003-8
Inflammatory Bowel Disease
Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study
J Crohns Colitis
Wewer MD, Lophaven S, Lakatos PL, Gonczi L, Salupere R, Kievit HAL, Nielsen KR, Midjord J, Domislovic V, Krznarić Ž, Pedersen N, Kjeldsen J, Halfvarson J, Sebastian S, Goldis A, Arebi N, Oksanen P, Neumann A, Andersen V, Katsanos KH, Koukoudis A, Turcan S, Ellul P, Kupcinskas J, Kiudelis G, Fumery M, Kaimakliotis IP, D'Inca R, Lombardini S, Hernandez V, Fernandez A, Langholz E, Munkholm P, Burisch J, Epi-IBD-group
doi: 10.1093/ecco-jcc/jjaf089
RECOMMENDED
Inflammatory Bowel Disease
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG
doi: 10.1016/S2468-1253(25)00129-3
Gastrointestinal Cancer
The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy
J Crohns Colitis
Visser E, Luberto A, Heuthorst L, Hompes R, Vermeire S, D'Haens GR, Bemelman WA, D'Hoore A, Bislenghi G, Buskens CJ
doi: 10.1093/ecco-jcc/jjaf015